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Follow up was with CXR at 6months followed by CT at 6 
months and clinical follow up, 3 monthly. 
 
Results: 167 patients with stage IA-IIB disease treated. 55% 
histologically proven.There were 4 (2.4%) radiologically 
confirmed local recurrences giving a local control rate of 
97.6%. Median survival was 43.2months. 3 year Overall 
Survival was 56.4% (see Fig 1). Treatment was well tolerated 
with minimal G3 toxicity (5 patients). 
 
Conclusion: Our results suggest that SABR for medically 
inoperable NSCLC can be safely and effectively implemented 
in a non-academic institution with appropriate equipment 
and training.Clinical outcomes are comparable with 
internationally published series [3}, with encouraging 3yr OS 
rate of 56%. Toxicity is minimal. Longer term follow-up is 
required to confirm findings and provide data regarding long-
term toxicity. 
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Purpose or Objective: In patients with inoperable stage I 
non-small cell lung cancer (NSCLC) or for those refusing 
surgery, stereotactic body radiotherapy and particle 
radiotherapy have become therapeutic options. We 
conducted a Phase I/II study on single-fraction carbon ion 
radiotherapy (SF-CIRT) for stage I NSCLC that yielded a 3-year 
survival rate of 75.5% for 218 patients. Until now, the effect 
of hypofractionated CIRT on pulmonary function (PF) has not 
been well documented. The purpose of this study was to 
assess the long-term impact of SF-CIRT on PF in stage I NSCLC 
patients. 
 
Material and Methods: A review of prospectively collected 
data from SF-CIRT-treated patients was performed. Patients 
underwent PF tests (PFT) (or: underwent a PF test) 
immediately before, and at 6, 12, and 24 months after 
irradiation. Patients who relapsed or needed adjuvant 
treatment were excluded as these events might affect PF.  
 
Results:  
 
 
Forty patients treated between 2007 and 2012 fulfilled the 
inclusion criteria. According to the dose escalation study 
protocol, a median prescribed single-fraction dose of 46 GyE 
(range, 44-50 GyE) was delivered. All treatment-related 
complications were self-limited, without any grade 3-5 
toxicities. Two years post-CIRT, the mean values of forced 
expiratory volume in 1 sec (FEV1) [-8.4% ± 11.9% (p < 0.001)] 
and the FEV1 per unit of forced vital capacity (FEV1/FVC) [-
8.9% ± 11.7% (p < 0.001)] were less than the pre-CIRT values. 
There were no significant overall changes in total lung 
capacity, vital capacity, FVC, and residual volume before SF-
CIRT and 2 years after SF-CIRT. At 6 months post-treatment, 
the diffusion capacity of the lung for carbon monoxide 
(DLCO) was significantly less than the pretreatment value 
(86.7 ± 32.7% vs. 78.1 ± 31.1%; p = 0.002); however, at 24 
months post-treatment, the mean DLCO recovered to 
pretreatment levels (86.9 ± 30.5%). This might have been due 
to recovery from non-symptomatic radiation pneumonitis 
and/or smoking cessation. 
 
 
 
Conclusion: We found stage I NSCLC patients had good long-
term preservation of PF after SF-CIRT. Follow-up PFT 
revealed the following: Declines in FEV1 and FEV1/FVC were 
statistically significant but clinically trivial, DLCO decreased 
temporary, thereafter it tended to recover to pretreatment 
levels within 2 years. 
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Purpose or Objective: An evaluation of thymic tumors 
patient radiotherapy results.  
 
Material and Methods: 93 patients (54F [58%], 39M [42%]) 
aged from 3 (6 children) to 77 (median 48) treated for thymic 
tumors since 1981. 84 patients (90%) were diagnosed with 
thymoma, 9 (10%) with thymic carcinoma. Masaoka stage was 
assessed in 93% (56% stage II, 31%-III, 6%- IV). All patients 
were irradiated. In 76 cases radiotherapy (RT) followed 
surgery – in 41 patients after radical and in 35 after 
incomplete resection. In 17 cases RT was definitive 
treatment, combined in 14 patients with chemotherapy. 
Patients were irradiated with fraction dose of 1.1-4.0Gy 
(median 2.0) to the total dose of 20-68Gy (median 49.5). 
Patient- and treatment-related factors potentially affecting 
survival and local control (LC) were evaluated with log-rank 
test. Survival analysis was performed with Kaplan-Meier 
method. 
 
Results: Tumors relapsed in 17 patients. Metastases occurred 
after 6-129months (median 10.1) in 12 patients (in 8 in 
lungs). During the follow-up 17 patients died due to 
progression(13) or recurrence(4) of the disease. Median 
overall survival (OS) in the whole group (since diagnosis) was 
140.2months. OS was significantly longer in patients with 
WHO B1 type(p=0.02), in good performance status 
(PS)(p=0.0005), without radiation-induced pulmonary 
fibrosis(p=0.02) or second cancer(p=0.03). Difference in OS 
between patients treated with radical surgery+RT, non-
radical surgery+RT and definitive RT was of borderline 
significance(p=0.065). Factors significantly decreasing LC 
were: male sex(p=0.04), WHO B2 type(p=0.01), bad 
PS(p=0.0007), presence of metastases(p=0.003) and second 
cancer(p=0.03).  
 
